

FRM-PS-0003 v. 4.0

KEAP Request Form for Selinexor

Effective: 16 Apr 2018

Karyopharm Use only: Forward Page 1 of this form, along with FRM-PS-0004 KEAP Order Form for Selinexor, to the Special Import License Holder and/or drug distribution vendors. File both forms in the appropriate KEAP repository.

Please send a signed electronic version of the completed form to: KEAP@karyopharm.com

Importation of unapproved medications for Expanded Access treatment (also known as Named Patient or Single Patient INDs) by Special Import Licence Holders requires the following information:

Name and Position of Treating Physician	of the						
Name of Treating Ho Institution	spital/						
Date of Application							
Briefly describe the disease	oatient's						
For regulatory filing purposes, will the treating physician or the treating hospital/institution be named on cross-reference letters to selinexor INDs or IMPDs (if applicable)? Treating Physician Treating Hospital/Institution							
In your medical opinion, are there any commercially-licensed treatments from which the patient would derive benefit? Yes No Briefly Explain:							
Are there any ongoing clinical trials (including selinexor clinical trials) which the patient qualifies for and could derive benefit from? Yes No							
If yes, can the patient reasonably access the clinical trial through an open clinical trial site? Yes No N/A Please explain:							
Treating Physician Signature					Date		
	•						
KARYOPHARM USE ONLY (to be completed by the assigned KEAP Team representative)							
KEAP Patient Tracking Number							
KARYOPHARM USE ONLY (to be completed by the assigned KEAP Team Leader)							
Karyopharm agrees to support this request for Expanded Access Program consideration.							
KEAP Team Leader Signature					Date		



FRM-PS-0003 v. 4.0

KEAP Request Form for Selinexor Effective: 16 Apr 2018

Karyopharm Use only: Forward Page 1 of this form, along with FRM-PS-0004 KEAP Order Form for Selinexor, to the Special Import License Holder and/or drug distribution vendors. File both forms in the appropriate KEAP repository.

Date of Application		Name of Treating Physician							
Please provide a summary of the patient's disease, past treatments, and current medical status.									
	, , , , , , , , , , , , , , , , , , , ,								
Treating Physician									
Signature			Date						
	NLY (to be completed by the KEAP Med								
	ent's current status and treatment hist	ory and determine if the pat	ient could derive	benefit from Expanded					
Access Treatment to selinexor alone or in combination.									
Are there any ongoing clinical trials (including selinexor clinical trials) which the patient qualifies for and could derive benefit from?									
☐ Yes ☐ No									
If yes, can the patient reasonably access the clinical trial through an open clinical trial site?									
☐ Yes ☐ No ☐ N/A									
Please explain:									
I approve this patient medically for KEAP consideration.									
Yes No Recommended treatment dosing:									
WEADAA-JI II									
KEAP Medical Lead Signature			Date						
Jigilature									